April 27, 2026 is a date the gene therapy field will not forget quickly. This morning at 8:00 a.m. ET, Intellia Therapeutics (Nasdaq: NTLA) is releasing topline data from its global Phase 3 HAELO clinical trial — and the significance of what is being reported extends well beyond a single therapy for a single disease. The distinction that makes today historic is the category of therapy being evaluated.
There are two approaches to CRISPR medicine. Ex vivo therapies remove a patient's cells, edit them in a laboratory, and reinfuse them. In vivo therapies deliver the gene-editing machinery directly into the body, targeting cells where they live — without removal, without laboratory processing, without the complex and costly manufacturing chain that ex vivo requires. In vivo is the harder scientific problem and the more scalable long-term solution. It has never before reached Phase 3 clinical evidence. Until today. The therapy under evaluation — lonvoguran ziclumeran, or lonvo-z — targets hereditary angioedema, a rare genetic condition characterised by unpredictable and potentially life-threatening episodes of severe swelling. The trial's key endpoints measure the number of attacks and the proportion of patients achieving attack-free status from week 5 through week 28.
Should the data prove supportive, Intellia plans to submit an application to the US FDA for approval in the second half of 2026. Markets have already responded to the anticipation — NTLA stock surged 21.79% following the announcement of the data release date on April 24. The scientific community is watching for a different reason. A successful Phase 3 readout for an in vivo CRISPR candidate does not just validate lonvo-z. It establishes the clinical framework — the trial design, the safety profile, the regulatory pathway — that every in vivo CRISPR programme that follows will be built on. This morning's data will set the standard for the next decade of gene medicine.
